Legal CBD Products With Trace THC Can Cause Positive Drug Tests in Oral Fluid

Even small amounts of THC in legal CBD products (as low as 0.5 mg) caused some participants to test positive for THC in oral fluid, and the rate of false positives increased dramatically with higher THC content — raising concerns for workplace drug testing.

Vikingsson, Svante et al.·Journal of analytical toxicology·2025·Strong Evidenceclinical-trial
RTHC-07874Clinical TrialStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
clinical-trial
Evidence
Strong Evidence
Sample
N=10

What This Study Found

After taking 100 mg CBD with just 0.5 mg THC (well within legal hemp limits), 1 in 10 participants tested positive for THC in oral fluid. At 2.8–3.7 mg THC (still in legal CBD products), 8 of 10 participants tested positive. Even in the CBD-only group, 5 samples tested positive due to trace CBD-to-THC conversion during analysis.

Key Numbers

100 mg CBD + 0.5 mg THC: 1/10 positive. + 1.0 mg: rate increased. + 2.8 mg: 8/10 positive. + 3.7 mg: 8/10 positive. CBD peaked at 2,198 ng/mL in oral fluid 30 min after dosing. 5 CBD-only samples positive due to analytical conversion. 14-day dosing + 7-day washout.

How They Did This

60 participants (n=10 per group) self-administered 100 mg CBD in MCT oil with 0, 0.5, 1.0, 2.0, 2.8, or 3.7 mg THC twice daily for 14 days, followed by 7-day washout. Oral fluid was tested by LC-MS/MS at a 2 ng/mL THC cutoff, along with CBD and metabolites.

Why This Research Matters

Millions of people use legal CBD products that may contain small amounts of THC. This study proves these products can trigger positive workplace drug tests, potentially costing people their jobs even when they've only used legal, non-intoxicating products.

The Bigger Picture

The finding that even CBD-only products can produce false positives (through analytical conversion of CBD to THC during testing) challenges the reliability of current oral fluid drug testing for distinguishing between legal hemp use and illegal THC use.

What This Study Doesn't Tell Us

Small groups (n=10 per condition). Controlled laboratory conditions may not reflect real-world product variability. Only oral fluid tested — urine and blood may differ. Specific to the 2 ng/mL cutoff used. MCT oil carrier may affect absorption differently than commercial products.

Questions This Raises

  • ?Should workplace drug testing cutoffs be adjusted to account for legal CBD use?
  • ?Are consumers adequately warned about drug testing risks on CBD product labels?
  • ?Should analytical methods be updated to prevent CBD-to-THC conversion artifacts?

Trust & Context

Key Stat:
Evidence Grade:
Well-controlled clinical study with multiple dose groups and validated analytical methods, though small group sizes limit precision of positive rate estimates.
Study Age:
Published 2025.
Original Title:
The Acute and Chronic Pharmacokinetic Oral Fluid Profile of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC) in Healthy Human Volunteers.
Published In:
Journal of analytical toxicology (2025)
Database ID:
RTHC-07874

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can I fail a drug test from taking CBD oil?

Yes. This study showed that even legal CBD products with very small amounts of THC (0.5 mg) caused some positive drug tests. Products with 2.8+ mg THC (still legal) caused positive tests in 80% of participants. If you face drug testing, discuss CBD use with your employer.

Do 'THC-free' CBD products also cause positive tests?

Potentially. Even in the CBD-only group (0 mg THC), 5 samples tested positive because trace amounts of CBD can convert to THC during the analytical process. Laboratories should be aware of this artifact.

Read More on RethinkTHC

Cite This Study

RTHC-07874·https://rethinkthc.com/research/RTHC-07874

APA

Vikingsson, Svante; Zamarripa, C Austin; Spindle, Tory R; Klausner, McKenna; Wolinsky, David; Cone, Edward J; Winecker, Ruth E; Flegel, Ronald R; Davis, Lisa S; Hayes, Eugene D; Kuntz, David; Vandrey, Ryan. (2025). The Acute and Chronic Pharmacokinetic Oral Fluid Profile of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC) in Healthy Human Volunteers.. Journal of analytical toxicology. https://doi.org/10.1093/jat/bkaf102

MLA

Vikingsson, Svante, et al. "The Acute and Chronic Pharmacokinetic Oral Fluid Profile of Oral Cannabidiol (CBD) With and Without Low Doses of Delta-9-Tetrahydrocannabinol (Δ9-THC) in Healthy Human Volunteers.." Journal of analytical toxicology, 2025. https://doi.org/10.1093/jat/bkaf102

RethinkTHC

RethinkTHC Research Database. "The Acute and Chronic Pharmacokinetic Oral Fluid Profile of ..." RTHC-07874. Retrieved from https://rethinkthc.com/research/vikingsson-2025-the-acute-and-chronic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.